drugset / Trial / NCT06971913
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.
Timeline
- Start
- 2025-05-20
- Primary completion
- 2025-09-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |
| Background | Ganciclovir | Small molecule | 5 mg/kg | Intravenous |